Perspectives on the Systemic Staging in Newly Diagnosed Breast Cancer.
Breast neoplasm
Cancer staging
Metastasis
Positron emission tomography
de novo
Journal
Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
08
10
2020
revised:
06
03
2021
accepted:
23
03
2021
pubmed:
9
5
2021
medline:
20
1
2022
entrez:
8
5
2021
Statut:
ppublish
Résumé
Breast cancer is a complex disease, and accurate systemic staging is an essential aspect of the evaluation of a patient with newly diagnosed breast cancer. Considering that the chance of having metastatic disease at breast cancer diagnosis is different in each patient and depends on a variety of anatomic and biologic factors, it is crucial to understand that some populations may benefit from more intensive staging because their pretest probability of metastatic disease is higher than that of the average patient. Identifying these patients with de novo stage IV breast cancer is associated with substantial prognostic and therapeutic implications. Unfortunately, recent advances in understanding breast cancer heterogeneity and molecular biology have not been incorporated in the international guidelines and recommendations about imaging examinations for detecting de novo metastatic breast cancer. This review article discusses important issues regarding the rationale for performing systemic staging, addresses current and innovative imaging methods, and proposes an algorithm for systemic staging in patients with newly diagnosed breast cancer.
Identifiants
pubmed: 33962905
pii: S1526-8209(21)00065-3
doi: 10.1016/j.clbc.2021.03.010
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-316Informations de copyright
Copyright © 2021. Published by Elsevier Inc.